StockNews.com Begins Coverage on Pro-Dex (NASDAQ:PDEX)

StockNews.com initiated coverage on shares of Pro-Dex (NASDAQ:PDEXGet Rating) in a research report released on Monday morning. The brokerage issued a hold rating on the medical instruments supplier’s stock.

Pro-Dex Stock Performance

NASDAQ:PDEX opened at $17.80 on Monday. The company’s 50-day moving average price is $18.05 and its 200-day moving average price is $17.04. The company has a current ratio of 2.73, a quick ratio of 1.39 and a debt-to-equity ratio of 0.41. The company has a market cap of $63.72 million, a P/E ratio of 17.12 and a beta of 0.94. Pro-Dex has a twelve month low of $12.40 and a twelve month high of $26.50.

Pro-Dex (NASDAQ:PDEXGet Rating) last released its quarterly earnings data on Thursday, August 25th. The medical instruments supplier reported $0.38 earnings per share (EPS) for the quarter. Pro-Dex had a net margin of 8.97% and a return on equity of 16.75%. The firm had revenue of $12.62 million during the quarter.

Institutional Trading of Pro-Dex

Several institutional investors have recently modified their holdings of the stock. Tower Research Capital LLC TRC increased its stake in Pro-Dex by 345.6% in the 3rd quarter. Tower Research Capital LLC TRC now owns 2,687 shares of the medical instruments supplier’s stock valued at $48,000 after buying an additional 2,084 shares during the period. Renaissance Technologies LLC purchased a new position in Pro-Dex in the 2nd quarter valued at about $168,000. State Street Corp lifted its holdings in shares of Pro-Dex by 5.8% during the 1st quarter. State Street Corp now owns 11,923 shares of the medical instruments supplier’s stock worth $197,000 after acquiring an additional 650 shares during the period. JPMorgan Chase & Co. lifted its holdings in shares of Pro-Dex by 59.2% during the 1st quarter. JPMorgan Chase & Co. now owns 20,863 shares of the medical instruments supplier’s stock worth $345,000 after acquiring an additional 7,762 shares during the period. Finally, LSV Asset Management increased its position in Pro-Dex by 13.9% during the 1st quarter. LSV Asset Management now owns 35,581 shares of the medical instruments supplier’s stock worth $588,000 after purchasing an additional 4,346 shares in the last quarter. Hedge funds and other institutional investors own 13.69% of the company’s stock.

Pro-Dex Company Profile

(Get Rating)

Pro-Dex, Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.

See Also

Receive News & Ratings for Pro-Dex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pro-Dex and related companies with MarketBeat.com's FREE daily email newsletter.